Evidence type
Explore PeptideScanner’s selected, source-linked ClinicalTrials.gov records by peptide, source year, and dated registry update.
721 selected, source-linked records.
32 profiles are connected to this evidence type.
721 distinct public records are cited.
Most recent source dates
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07087795 at 2026-08-13T16:32:13.881Z. Its registry update date was 2026-08-13, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT03883412 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Dulaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05478707 at 2026-08-13T05:54:14.860Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was dulaglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-08-13T05:54:14.856Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07046819 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07218354 at 2026-08-13T05:54:14.857Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07734870 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Survodutide
PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-08-13T05:52:27.018Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was survodutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06965413 at 2026-08-13T05:52:27.007Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06651177 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT03884075 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Survodutide
PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.
Source: ClinicalTrials.gov ↗
Connected profiles
2005–2026